Anti-TROY/TNFRSF19 Rabbit Monoclonal Antibody for WB and ELISA - Q9NS68

Core Product Specifications and Parameters

Biological Background: TROY/TNFRSF19 Function and Localization

• TROY, also known as TAJ, TRADE, and TAJ-alpha, is encoded by the TNFRSF19 gene and belongs to the tumor necrosis factor receptor superfamily.
• It functions as a receptor that can mediate activation of the JNK pathway and NF-kappa-B signaling.
• TROY may promote caspase-independent cell death, implicating it in programmed cell death mechanisms.
• The protein is localized to the plasma membrane as a single-pass transmembrane receptor with an extracellular domain containing disulfide bonds and glycosylation sites.
• TROY is highly expressed in the prostate, with lower detection in thymus, spleen, testis, uterus, small intestine, colon, and peripheral blood leukocytes.
• Keywords indicate it undergoes alternative splicing, is a glycoprotein, and contains a signal peptide and transmembrane helix.
• The predicted molecular weight is approximately 46 kDa (UniProt: 46,015 Da), consistent with the reported protein weight of 46 kDa.

Experimental Guidance and Technical Tips

• For Western blot, optimize antibody dilution to detect the ~46 kDa TROY band in cell or tissue lysates, particularly from prostate or other known expressing tissues.
• The immunogen targets amino acids 100–200 within the extracellular domain, potentially recognizing variants produced by alternative splicing; confirm specificity in the relevant sample system.
• In ELISA, titrate the antibody to establish optimal binding conditions, using recombinant TROY protein or cell-based assays as positive controls.
• Cross-reactivity with mouse and rat allows for comparative studies; however, validate performance in your specific assay and sample type.
• Consider using blocking agents and incubation times standard for rabbit monoclonal antibodies to reduce nonspecific binding.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio is your integrated partner for IVD raw-material procurement, offering this anti-TROY/TNFRSF19 antibody alongside complementary reagents such as validated antibody pairs, optimized monoclonal/polyclonal antibodies, and bulk ancillary materials. Our supply capabilities support research into apoptosis, NF-kappa-B signaling, and cancer biology, enabling seamless transition from concept to clinical application. For customized raw-material needs or technical consulting, our team provides end-to-end support to streamline your IVD development workflow.